Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the Perugia Consensus Conference

Annals of Oncology

Volumn 9, Issue 8, 1998, Pages 811-819

  Roila, F ^a  

^a Policlinico Hospital   (Italy)

Author keywords

5 HT3 antagonists; Antiemetics; Chemotherapy and radiotherapy induced emesis

Indexed keywords

ALIZAPRIDE; ALPRAZOLAM; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CANNABINOID; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOLASETRON MESILATE; DOXORUBICIN; DROPERIDOL; EPIRUBICIN; FLUOROURACIL; GRANISETRON; LORAZEPAM; METHOTREXATE; METHYLPREDNISOLONE; METOCLOPRAMIDE; METOPIMAZINE; NAVELBINE; ONDANSETRON; PHENOTHIAZINE DERIVATIVE; SEROTONIN 3 ANTAGONIST; TROPISETRON; UNINDEXED DRUG; VINBLASTINE;

ANTIEMETIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CORTICOSTEROID THERAPY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROPHYLAXIS; RADIATION SICKNESS; VOMITING;

ADULT; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CHILD; DEXAMETHASONE; HUMANS; METOCLOPRAMIDE; NEOPLASMS; RADIOTHERAPY; SEROTONIN ANTAGONISTS; VOMITING; VOMITING, ANTICIPATORY;

EID: 0031691344     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008471812316     Document Type: Article

References (103)

1. Ballatori E, Roila F, De Angelis V et al. Clinical and methodological issues in antiemetic therapy: A worldwide survey of experts' opinions. Support Care Cancer 1997; 5: 269-73.
2. Hesketh PJ, Kris MG, Grunberg SM et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997; 15: 103-9.
3. Tonato M, Roila F, Del Favero A. Methodology of antiemetic trials: A review. Ann Oncol 1991; 2: 107-14.
4. Kris MG, Gralla RJ, Clark RA et al. Antiemetic control and prevention of side effects of anticancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial. Cancer 1987; 60: 2816-22.
5. Del Favero A, Roila F, Tonato M. Reducing chemotherapy-induced nausea and vomiting. Current perspectives and future possibilities. Drug Safety 1993; 9: 410-28.
6. Roila F, Tonato M, Ballatori E, Del Favero A. Comparative studies of various antiemetic regimes. Support Care Cancer 1996; 4:270-80.
7. Italian Group for Antiemetic Research. Ondansetron + dexamethasone versus metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Lancet 1992; 340: 96-9.
8. Cunningham D, Dicato M, Verweij J, et al. Optimum antiemetic therapy for cisplatin induced emesis over repeat courses: Ondansetron plus dexamethasone compared with metoclopramide, dexamethasone plus lorazepam. Ann Oncol 1996; 7: 277-82.
9. Italian Group for Antiemetic Research. Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. J Clin Oncol 1993; 11: 2396-404.
10. Herrstedt J, Sigsgaard T, Handberg J et al. Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in cancer patients. J Clin Oncol 1997; 15: 1690-6.
11. 3 receptor antagonists the same? Eur J Cancer 1992; 28A (Suppl 1): 2-6.
12. 3 receptor antagonists: Differences and similarities. Eur J Cancer 1997; 33: 1364-70.
13. Beck TM, Hesketh PJ, Madajewicz S et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1992; 10: 1969-75.
14. Seynaeve C, Schuller J, Buser K et al. Comparison of the antiemetic efficacy of different doses of ondansetron given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Br J Cancer 1992; 66: 192-7.
15. Ruff P, Paska W, Goedhals L et al. on behalf of the Ondansetron and Granisetron Emesis Study Group. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: A multicentre double-blind, randomised, parallel group study. Oncology 1994; 51: 113-8.
16. Italian Group for Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 1995; 6: 805-10.
17. Navari RM, Kaplan HG, Gralla RJ et al. Efficacy and safety of granisetron, a selective 5-Hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 1994; 12: 2204-10.
18. Riviere A on behalf of the Granisetron Study Group. Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. Br J Cancer 1994; 69: 967-71.
19. Soukop M on behalf of the Granisetron Study Group. A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Support Care Cancer 1994; 2: 177-83.
20. Navari R, Hesketh P, Hall S et al. on behalf of the Granisetron Study Group. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995; 13: 1242-8.
21. Van Belle SJP, Stamatakis L, Bleiberg H et al. Dose-finding study of tropisetron in cisplatin-induced nausea and vomiting. Ann Oncol 1994; 5: 821-5.
22. Marty M, Kleisbauer J-P, Fournel P et al. Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? Anti-Cancer Drugs 1995; 6: 15-21.
23. Hesketh P, Navari R, Grote T et al. for the Dolasetron Comparative Chemotherapy-induced Emesis Preventive Group. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 1996; 14: 2242-9.
24. Thant M, Pendergrass K, Harman G et al. Double-blind, randomized study of the dose-response relationship across five single doses of i.v. dolasetron mesylate for the prevention of acute nausea and vomiting after cisplatin chemotherapy. Proc Am Soc Clin Oncol 1996; 15: 533.
25. Gralla RJ, Popovic W, Strupp J et al. Can an oral antiemetic regimen be as effective as intravenous treatment against cisplatin: Results of a 1054 patient randomized study of oral granisetron versus i.v. ondansetron. Proc Am Soc Clin Oncol 1997; 16: 52a.
26. Krzakowski M, Graham E, Goedhals L et al. Control of acute cisplatin-induced nausea and emesis using a once daily oral treatment regimen of ondansetron plus dexamethasone. Eur J Cancer 1997; 33 (Suppl 8): 19.
27. Kris MG, Pendergrass KB, Navari RM et al. Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone. J Clin Oncol 1997; 15: 2135-8.
28. Aapro MS. Present role of corticosteroids as antiemetics. In Senn H-J, Glaus A (eds): Recent Results in Cancer Research. Berlin: Springer 1991; 91-100.
29. Kris MG, Gralla RJ, Clark RA et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985; 3: 108-14.
30. Navari R, Madajewicz S, Anderson N et al. Oral ondansetron for the control of cisplatin-induced delayed emesis: A large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol 1995; 13: 2408-16.
31. Johnston D, Latreille J Laberge F et al. Preventing nausea and vomiting during days 2-7 following high-dose cisplatin chemotherapy: A study by the National Cancer Institute of Canada Clinical Trials Group. Proc Am Soc Clin Oncol 1995; 14: 529.
32. Kris MG, Gralla RJ, Tyson LB et al. Controlling delayed vomiting: Double-blind, randomized trial comparing placebo, dexamethasone alone and metoclopramide plus dexamethasone in patients receiving cispatin. J Clin Oncol 1989; 7: 108-14.
33. Moreno I, Rosell R, Abad A et al. Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients. Eur J Cancer 1992; 28A: 1344-7.
34. The Italian Group for Antiemetic Research. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. J Clin Oncol 1997; 15: 124-30.
35. Italian Group for Antiemetic Research. Cisplatin-induced delayed emesis: Pattern and prognostic factors during three subsequent cycles. Ann Oncol 1994; 5: 585-9.
36. Bonneterre J, Chevallier B, Metz R et al. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil and doxorubicin or epirubicin chemotherapy. J Clin Oncol 1990; 8: 1063-9.
37. Kaasa S, Kvaloy S, Dicato MA et al. A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: A randomized, double-blind study. Eur J Cancer 1990; 26: 311-4.
38. Anderson H, Thatcher N, Howell A et al. Tropisetron compared with a metoclopramide-based regimen in the prevention of chemotherapy-induced nausea and vomiting. Eur J Cancer 1994; 30A: 610-5.
39. Fauser A, Bleiberg H, Chevallier B et al. A double-blind, randomized, parallel study of iv dolasetron versus i.v. metoclopramide in patients receiving moderately emetogenic chemotherapy. Cancer J 1996; 9: 196-201.
40. Campora E, Giudici S, Merlini L et al. Ondansetron and dexamethasone versus standard combination antiemetic therapy. Am J Clin Oncol (CCT) 1994; 17: 522-6.
41. Clavel M, Bonneterre J, d'Allens H, and the French Ondansetron Study Group. Oral ondansetron in the prevention of chemo-therapy-induced emesis in breast cancer patients. Eur J Cancer 1995; 31A: 15-9.
42. De Nigris A, Paladini G, Giosa F et al. Tropisetron (Navoban) compared with alizapride in the control of emesis induced by cyclophosphamide-containing regimens. Eur J Cancer 1994; 30A: 1902-3.
43. Palmer R, Moriconi W, Cohn J et al. A double-blind comparison of the efficacy and safety of oral granisetron with oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy. Proc Am Soc Clin Oncol 1995; 14: 528.
44. 3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. Eur J Cancer 1990; 26 (Suppl 1): 28-32.
45. Warr D, Willan A, Fine S et al. Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis. J Natl Cancer Inst 1991; 83: 1169-73.
46. Jones AL, Hill AS, Soukop M et al. Comparison of dexamethasone in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 1991; 338: 483-7.
47. The Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995; 332: 1-5.
48. The Italian Group for Antiemetic Research. Persistence of efficacy of three antiemetic regimens and prognostic factors in patients undergoing moderately emetogenic chemotherapy. J Clin Oncol 1995; 13: 2417-26.
49. Soukop M, McQuade B, Hunter E et al. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology 1992; 49: 295-304.
50. du Bois A, McKenna CJ, Andersson H et al. A randomised, double-blind, parallel-group study to compare the efficacy and safety of ondansetron (GR38032F) plus dexamethasone with metoclopramide plus dexamethasone in the prophylaxis of nausea and emesis induced by carboplatin chemotherapy. Oncology 1997; 54: 7-14.
51. Beck TM, Ciociola AA, Jones SE et al. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med 1993; 118: 407-13.
52. 3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Am J Clin Oncol (CCT) 1994; 17: 137-46.
53. Kaizer L, Warr D, Hoskins P et al. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: A phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994; 12: 1050-7.
54. Dicato M. Oral treatment with ondansetron in an outpatient setting. Eur J Cancer 1991; 27 (Suppl 1): 518-9.
55. Hacking A, on behalf of the Granisetron Study Group. Oral granisetron-simple and effective: A preliminary report. Eur J Cancer 1992; 28A (Suppl 1): 28-32.
56. Bleiberg HH, Spielmann M, Falkson G et al. Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: A dose-ranging study. Clin Therapeut 1995; 17: 38-51.
57. Ettinger DS, Eisenberg PD, Fitts D et al. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy. Cancer 1996; 78: 144-51.
58. Rubenstein EB, Gralla RJ, Hainsworth JD et al. Randomized, double-blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Cancer 1997; 79: 1216-24.
59. Koo WH, Ang PT. Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy. Ann Oncol 1996; 7: 71-4.
60. 3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann Oncol 1997; 8: 181-5.
61. The Italian Group for Antiemetic Research. Delayed emesis induced by moderately emetogenic chemotherapy: Do we need to treat all patients? Ann Oncol 1997; 8: 561-7.
62. Sledge GW, Einhorn L, Nagy C et al. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer 1992; 70: 2524-8.
63. Bremer K on behalf of the Granisetron Study Group. A single-blind study of the efficacy and safety of intravenous granisetron compared with alizapride plus dexamethasone in the prophylaxis and control of emesis in patients receiving five-day cytostatic therapy. Eur J Cancer 1992; 28A: 1018-22.
64. The Granisetron Study Group. The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over five days. J Cancer Res Clin Oncol 1993; 119: 555-9.
65. Rath U, Upadhyaya BK, Arechavala E et al. Role of ondansetron plus dexamethasone in fractionated chemotherapy. Oncology 1993; 50: 168-72.
66. Nicolai N, Mangiarotti B, Salvioni R et al. Dexamethasone plus ondansetron versus dexamethasone plus alizapride in the prevention of emesis induced by cisplatin-containing chemotherapies for urological cancers. Eur Urol 1993; 23: 450-6.
67. Fox SM, Einhorn LH, Cox E et al. Ondansetron vs ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy. J Clin Oncol 1993; 11: 2391-5.
68. Levitt M, Warr D, Yelle L et al. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate and fluorouracil. N Engl J Med 1993; 328: 1081-4.
69. Buser KS, Joss RA, Piquet D et al. Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind placebo-controlled study. Ann Oncol 1993; 4: 474-9.
70. Herrstedt J, Sigsgaard T, Boesgaard M et al. Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med 1993; 328: 1076-80.
71. Lebeau B, Depierre A, Giovannini M et al. The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. Ann Oncol 1997; 8: 887-92.
72. Morrow GR, Roscoe JA. Anticipatory nausea and vomiting: Models, mechanisms and management. In Dicato M (ed): Medical Management of Cancer Treatment Induced Emesis. London: Martin Dunitz Ltd 1997; 149-66.
73. Aapro MS, Kirchner V, Terrey JP. The incidence of anticipatory nausea and vomiting after repeat cycle chemotherapy: The effect of granisetron. Br J Cancer 1994; 69: 957-60.
74. Morrow GR, Roscoe JA, Hynes J et al. Progress in reducing anticipatory nausea and vomiting: A study of community practice. Support Care Cancer 1998; 6: 46-50.
75. Razavi D, Delvaux N, Farvacques C et al. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: A double-blind, placebo-controlled study assessing the usefulness of alprazolam. J Clin Oncol 1993; II: 1384-90.
76. Morrow GR. Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. N Engl J Med 1982; 306: 431-2.
77. Zeltzer LK, Dolgin M, LeBaron S et al. A randomized, controlled study of behavioral intervention for chemotherapy distress in children with cancer. Pediatrics 1991; 88: 34-42.
78. Agura ED, Cleveland Brown M et al. Anti-emetic efficacy and pharmacokinetics of intravenous ondansetron infusion during chemotherapy conditioning for bone marrow transplant. BMT 1995; 16: 213-22.
79. Bosi A, Guidi S, Messori A et al. Ondansetron versus chlorpromazine for preventing emesis in bone marrow transplant recipients: A double-blind randomized study. J Chemother 1993; 5: 191-6.
80. Okamoto S, Takahashi S, Tanosaki R et al. Granisetron in the prevention of vomiting induced by conditioning for stem cell transplantation: A prospective randomized study. BMT 1996; 17: 679-83.
81. Priestman TJ, Roberts JT, Lucraft H et al. Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation. Clin Oncol 1990; 2: 71-5.
82. Collis CH, Priestman TJ, Priestman S et al. The final assessment of a randomized double-blind comparative study of ondansetron vs. metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation. Clin Oncol 1991; 3: 241-2.
83. Bey P, Wilkinson PM, Resbeut M et al. A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients. Support Care Cancer 1996; 4: 378-83.
84. Priestman TJ, Roberts JT, Upadhyaya BK. A prospective randomized double-blind trial comparing ondansetron versus prochlorperazine for the prevention of nausea and vomiting in patients undergoing fractionated radiotherapy. Clin Oncol 1993; 5: 358-63.
85. Franzen L, Nyman J, Hagberg H et al. A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy. Ann Oncol 1996; 7: 587-92.
86. Spitzer TR, Bryson JC, Cirenza E et al. Randomized double-blind, placebo-controlled evaluation of oral ondansetron in the prevention of nausea and vomiting associated with fractionated total-body irradiation. J Clin Oncol 1994; 12: 2432-8.
87. Prentice HG, Cunningham S, Gandhi L et al. Granisetron in the prevention of irradiation-induced emesis. BMT 1995; 15: 445-8.
88. Sykes AJ, Kiltie AE, Stewart AL. Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: A prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy. Support Care Cancer 1997; 5: 500-3.
89. Roberts JT, Priestman TJ. A review of ondansetron in the management of radiotherapy-induced emesis. Oncology 1993; 50: 173-9.
90. Mirabell R, Coucke P, Behrouz F et al. Nausea and vomiting in fractionated radiotherapy: A prospective on-demand trial of tropisetron rescue for non-responders to metoclopramide. Eur J Cancer 1995; 31A: 1461-4.
91. Graham-Pole J, Weare J, Engel S et al. Antiemetics in children receiving cancer chemotherapy: A double-blind prospective randomized study comparing metoclopramide with chlorpromazine. J Clin Oncol 1986; 4: 1110-3.
92. Metha P, Gross S, Graham-Pole J, Gardner R. Methylprednisolone for chemotherapy-induced emesis: A double-blind randomized trial in children. J Pediatr 1986; 108: 774-6.
93. Marshall G, Kerr S, Vowels M et al. Antiemetic therapy for chemotherapy-induced vomiting: Metoclopramide, benztropine, dexamethasone, and lorazepam regimen compared with chlorpromazine alone. J Pediatr 1989; 115: 156-60.
94. Swann IL, Thompson EN, Qureshi K. Domperidone or metoclopramide in preventing chemotherapeutically induced nausea and vomiting. BMJ 1979; 2: 1979.
95. Zeltzer L, LeBaron S, Zeltzer PM. Paradoxical effects of prophylactic phenothiazine antiemetics in children receiving chemotherapy. J Clin Oncol 1984; 2: 930-6.
96. Chan HSL, MacLeod SM, Correia JA. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: A double-blind, crossover trial. Pediatrics 1987; 79: 946-52.
97. Dalzell AM, Bartlett H, Lilleyman JS. Nabilone: An alternative antiemetic for cancer chemotherapy. Arch Dis Child 1986; 61: 502-5.
98. Ekert H, Waters KD, Jurg IH et al. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetra-hydrocannabinol. Med J Austr 1992; 2: 657-9.
99. Alvarez O, Freeman A, Bedros A et al. Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies. J Pediatr Hematol Oncol 1995; 17: 145-50.
100. Dick GS, Meller ST, Pinkerton CR. Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis. Arch Dis Child 1995; 73: 243-5.
101. Hählen K, Quintana E, Pinkerton CR, Cedar E. A randomized comparison of intravenously administered granisetron versus chlorpromazine plus dexamethasone in the prevention of ifosfamide-induced emesis in children. J Pediatr 1995; 126: 309-13.
102. Hirota T, Honjo T, Kuroda R et al. Antiemetic efficacy of granisetron in paediatric cancer treatment. Comparison of granisetron and granisetron plus methylprednisolone as antiemetic prophylaxis. Gan To Kagaku Ryoho 1993; 20: 2369-73.
103. 1 receptor antagonist to prevent delayed emesis after cisplatin. J Natl Cancer Inst 1997; 89: 817-8.